Plasma Biomarkers C-RAC, ICORG 12-27, V1

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

NCT06194877 ·Status: TERMINATED ·Phase: PHASE1

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT01075048 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

NCT05201612 ·Status: UNKNOWN ·Phase: PHASE2

Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy

NCT03010722 ·Status: COMPLETED

Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis

NCT02784639 ·Status: COMPLETED ·Phase: NA

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

NCT01538680 ·Status: NO_LONGER_AVAILABLE

Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

NCT00258232 ·Status: COMPLETED ·Phase: PHASE2

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

NCT01367275 ·Status: TERMINATED ·Phase: PHASE2

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

NCT01057017 ·Status: TERMINATED ·Phase: PHASE2

Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)

NCT00483080 ·Status: COMPLETED ·Phase: PHASE2

Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer

NCT01126112 ·Status: COMPLETED ·Phase: PHASE2

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

NCT04073615 ·Status: TERMINATED ·Phase: PHASE1

RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

NCT02452970 ·Status: TERMINATED ·Phase: PHASE2

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

NCT01776307 ·Status: COMPLETED ·Phase: PHASE2

Comprehensive Immune-landscape in Localized Colorectal Cancer

NCT02138370 ·Status: UNKNOWN

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab

NCT02175654 ·Status: TERMINATED ·Phase: PHASE2

Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer

NCT00559676 ·Status: COMPLETED ·Phase: PHASE4

Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients

NCT01453257 ·Status: COMPLETED ·Phase: PHASE2

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

NCT04294160 ·Status: TERMINATED ·Phase: PHASE1

Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer

NCT01387880 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

NCT00582660 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

NCT01032291 ·Status: TERMINATED ·Phase: PHASE2

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

NCT03035279 ·Status: TERMINATED ·Phase: PHASE1

Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer

NCT02751177 ·Status: COMPLETED ·Phase: NA